Author: Andrew

Leverage MIT’s new seed-dispersal index to de-risk nature credits, boost carbon yields up to 4x, and align with TNFD, VERRA, and Gold Standard.

L4TE’s MIT/Brigham integrated studio merges fabrication, bioanalytics, and in vivo teams to cut time-to-EFS by 30% and accelerate first-in-human by 6…

Discover how MIT’s neurally integrated bionic knee delivers 25% fewer falls, 0.20 m/s gait gains, and a 3.5-year payback to reshape prosthetics economics.

Achieve 20% faster charging and 15% weight reduction with graphene/CNT solutions. Learn 90-day pilots, KPIs, EHS, and governance for seamless scale.

MIT used generative AI to design 36M molecules and find novel antibiotics against MRSA and drug‑resistant gonorrhea. Expect faster, cheaper R&D and…

Biotech embryo models, AWS DNS outage fragility, AI safety, Anthropic in life sciences, Amazon automation, and AI safety tools—what leaders must do now.

Discover how noninvasive endometriosis tests can halve diagnostic lag, reduce surgical costs 40%, boost IVF success by 10%, and unlock a $12B global ROI.

Stem‑cell embryo models edge toward fetus‑like stages. The race to commercialize spans IVF, regen med and IP, but legal and reputational risks loom.

AI that ends unhealthy or unproductive chats can cut costs, protect users, and meet new rules. Here’s the strategic case, guardrails, and a pragmatic…

How hospitals can adopt AI CAC scoring on routine chest CTs—separate hype from value, integrate with EHRs, manage risk, and scale with a phased roadmap.